Defence Therapeutics Inc. (FRA:DTC)

Market Cap	23.12M -36.9%
Revenue (ttm)	n/a
Net Income	-2.69M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8,712
Open	0.3600
Previous Close	0.4170
Day's Range	0.3600 - 0.3600
52-Week Range	0.3170 - 1.1700
Beta	n/a
RSI	51.54
Earnings Date	Feb 23, 2026

About Defence Therapeutics

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DTC

Financial Performance

Financial numbers in CAD